LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 1 | C20 | 72 | hr | 1401 | 864 | 4223 | 0.2046 | -0.1905 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 2 | C20 | 72 | hr | 1401 | 733 | 4223 | 0.1736 | -0.2369 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP5 | 3 | C20 | 72 | hr | 1401 | 793 | 4223 | 0.1878 | -0.2157 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 1 | C20 | 72 | hr | 1401 | 693 | 4223 | 0.1641 | -0.2511 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 2 | C20 | 72 | hr | 1401 | 598 | 4223 | 0.1416 | -0.2848 |
| SK-BR-3 | Mitoxantrone | 3.33 | uM | LJP6 | 3 | C20 | 72 | hr | 1401 | 787 | 4223 | 0.1864 | -0.2178 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 1 | F02 | 72 | hr | 1401 | 2156 | 4223 | 0.5105 | 0.2674 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 2 | F02 | 72 | hr | 1401 | 2194 | 4223 | 0.5195 | 0.2809 |
| SK-BR-3 | MK2206 | 3.33 | uM | LJP6 | 3 | F02 | 72 | hr | 1401 | 2205 | 4223 | 0.5221 | 0.2848 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 1 | A14 | 72 | hr | 1401 | 1413 | 4223 | 0.3346 | 0.0041 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 2 | A14 | 72 | hr | 1401 | 1549 | 4223 | 0.3668 | 0.0523 |
| SK-BR-3 | Neratinib | 3.33 | uM | LJP5 | 3 | A14 | 72 | hr | 1401 | 1285 | 4223 | 0.3043 | -0.0413 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 1 | N14 | 72 | hr | 1401 | 4421 | 4223 | 1.0469 | 1.0701 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 2 | N14 | 72 | hr | 1401 | 4912 | 4223 | 1.1631 | 1.2442 |
| SK-BR-3 | Nilotinib | 3.33 | uM | LJP5 | 3 | N14 | 72 | hr | 1401 | 4890 | 4223 | 1.1579 | 1.2364 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 1 | H02 | 72 | hr | 1401 | 3370 | 4223 | 0.7980 | 0.6977 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 2 | H02 | 72 | hr | 1401 | 3285 | 4223 | 0.7779 | 0.6675 |
| SK-BR-3 | Nintedanib | 3.33 | uM | LJP6 | 3 | H02 | 72 | hr | 1401 | 3184 | 4223 | 0.7540 | 0.6317 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 1 | C08 | 72 | hr | 1401 | 3772 | 4223 | 0.8932 | 0.8401 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 2 | C08 | 72 | hr | 1401 | 3049 | 4223 | 0.7220 | 0.5839 |
| SK-BR-3 | NU7441 | 3.33 | uM | LJP5 | 3 | C08 | 72 | hr | 1401 | 3011 | 4223 | 0.7130 | 0.5704 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 1 | M14 | 72 | hr | 1401 | 1612 | 4223 | 0.3817 | 0.0746 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 2 | M14 | 72 | hr | 1401 | 1556 | 4223 | 0.3685 | 0.0547 |
| SK-BR-3 | Dactolisib | 3.33 | uM | LJP5 | 3 | M14 | 72 | hr | 1401 | 1514 | 4223 | 0.3585 | 0.0399 |
| SK-BR-3 | NVP-TAE684 | 3.33 | uM | LJP6 | 1 | K14 | 72 | hr | 1401 | 2127 | 4223 | 0.5037 | 0.2571 |